checkAd

     113  0 Kommentare More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment

    Für Sie zusammengefasst
    • aap successfully accelerated recruitment in clinical trial with adapted study design in 2023.
    • Over 100 patients recruited by December 2023, recruitment phase expected to be completed in 2024.
    • aap's antibacterial implant technology aims to counter antibiotic resistance and expects market launch in three years.


    EQS-Media / 10.01.2024 / 07:30 CET/CEST

    With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and has already successfully recruited more than 100 patients by 31 December 2023.

    aap currently assumes that the recruitment phase will be completed as planned in the course of 2024, involving up to 14 clinical trial centers. Further successful compassionate use cases make aap optimistic that corresponding results will also be achieved in the human clinical trial.

    With its pioneering antibacterial implant technology, in which elemental silver is incorporated into the implant surface in a very low but highly effective concentration, aap is striving for a unique selling point that effectively counters the increasing resistance to antibiotics in medicine and has the potential to become the gold standard in traumatology. Depending on the human clinical trial and the regulatory authorities, aap expects the first market launch of its new technology in three years.

    In addition to the human clinical trial, the company will increasingly participate in events organized by medical and scientific associations at national and international level in the coming months in order to raise awareness of its disruptive technology on the global market and make initial preparations for a market launch.

    The licensing of aap's innovative antibacterial implant technology for other indications is also to be further advanced in the course of 2024, with initial commercialization opportunities already emerging.

    The human clinical study is funded by the Federal Ministry of Education and Research ("BMBF"). The grant awarded to the company (funding codes 13GW0313A+B, 13GW0449A+B) is part of the "Healthcare industry" field of action in the BMBF's Health Research Framework Program (= funding body). According to the BMBF, projects on the topic of "Transferring medical technology solutions to patient care - proving clinical evidence without delay" are being funded. For further information, please refer to the relevant guidelines on the BMBF website: https://www.bmbf.de/foerderungen/bekanntmachung-1376.html.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment EQS-Media / 10.01.2024 / 07:30 CET/CEST With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and …

    Schreibe Deinen Kommentar

    Disclaimer